Alemtuzumab-associated diffuse alveolar damage – a case report

BACKGROUND: Identifying causes of alemtuzumab induced respiratory symptoms in Multiple Sclerosis (MS) patients is crucial. CASE PRESENTATION: We report a case of diffuse alveolar damage (DAD) in a patient with MS after the first course of alemtuzumab treatment. A 42-year-old female developed progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayas, Antonios, Menacher, Martina, Schwaiblmair, Martin, Märkl, Bruno, Naumann, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510011/
https://www.ncbi.nlm.nih.gov/pubmed/32967641
http://dx.doi.org/10.1186/s12883-020-01934-7
_version_ 1783585704658337792
author Bayas, Antonios
Menacher, Martina
Schwaiblmair, Martin
Märkl, Bruno
Naumann, Markus
author_facet Bayas, Antonios
Menacher, Martina
Schwaiblmair, Martin
Märkl, Bruno
Naumann, Markus
author_sort Bayas, Antonios
collection PubMed
description BACKGROUND: Identifying causes of alemtuzumab induced respiratory symptoms in Multiple Sclerosis (MS) patients is crucial. CASE PRESENTATION: We report a case of diffuse alveolar damage (DAD) in a patient with MS after the first course of alemtuzumab treatment. A 42-year-old female developed progressive non-productive cough and exertional dyspnea 2 months after alemtuzumab treatment. DAD was diagnosed histopathologically by lung biopsy. The patient recovered completely, alemtuzumab was not continued. CONCLUSIONS: Our case highlights another pathomechanism for non-infective lung-disorders in alemtuzumab treated MS patients. DAD is a potential, albeit rare side effect of alemtuzumab, broadening the spectrum of non-infective lung disorders that should be considered in the diagnostic work-up.
format Online
Article
Text
id pubmed-7510011
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75100112020-09-23 Alemtuzumab-associated diffuse alveolar damage – a case report Bayas, Antonios Menacher, Martina Schwaiblmair, Martin Märkl, Bruno Naumann, Markus BMC Neurol Case Report BACKGROUND: Identifying causes of alemtuzumab induced respiratory symptoms in Multiple Sclerosis (MS) patients is crucial. CASE PRESENTATION: We report a case of diffuse alveolar damage (DAD) in a patient with MS after the first course of alemtuzumab treatment. A 42-year-old female developed progressive non-productive cough and exertional dyspnea 2 months after alemtuzumab treatment. DAD was diagnosed histopathologically by lung biopsy. The patient recovered completely, alemtuzumab was not continued. CONCLUSIONS: Our case highlights another pathomechanism for non-infective lung-disorders in alemtuzumab treated MS patients. DAD is a potential, albeit rare side effect of alemtuzumab, broadening the spectrum of non-infective lung disorders that should be considered in the diagnostic work-up. BioMed Central 2020-09-23 /pmc/articles/PMC7510011/ /pubmed/32967641 http://dx.doi.org/10.1186/s12883-020-01934-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Bayas, Antonios
Menacher, Martina
Schwaiblmair, Martin
Märkl, Bruno
Naumann, Markus
Alemtuzumab-associated diffuse alveolar damage – a case report
title Alemtuzumab-associated diffuse alveolar damage – a case report
title_full Alemtuzumab-associated diffuse alveolar damage – a case report
title_fullStr Alemtuzumab-associated diffuse alveolar damage – a case report
title_full_unstemmed Alemtuzumab-associated diffuse alveolar damage – a case report
title_short Alemtuzumab-associated diffuse alveolar damage – a case report
title_sort alemtuzumab-associated diffuse alveolar damage – a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510011/
https://www.ncbi.nlm.nih.gov/pubmed/32967641
http://dx.doi.org/10.1186/s12883-020-01934-7
work_keys_str_mv AT bayasantonios alemtuzumabassociateddiffusealveolardamageacasereport
AT menachermartina alemtuzumabassociateddiffusealveolardamageacasereport
AT schwaiblmairmartin alemtuzumabassociateddiffusealveolardamageacasereport
AT marklbruno alemtuzumabassociateddiffusealveolardamageacasereport
AT naumannmarkus alemtuzumabassociateddiffusealveolardamageacasereport

Ejemplares similares